WARNINGS

- Vaccine administration should be postponed for the following patients: those with a fever of 38°C and above, those with an undiagnosed acute disease, and those with acute exacerbation of chronic diseases.
- Until further notice, healthcare workers who have had COVID-19 are going to receive the vaccine a month after recovering from the disease due to being members of the group with the highest exposure to the virus. Other individuals in high-risk groups may receive the vaccine six months after recovering from COVID-19.
- There is no data on the application of the inactivated Pandemic COVID-19 vaccine (CoronaVac) during pregnancy. Pregnant women at high risk of having COVID-19 with a possible severe course can be vaccinated upon request. It is suggested that vaccination should be avoided during the first trimester.
- There is no data on the administration of the inactivated Pandemic COVID-19 vaccine (CoronaVac) during breastfeeding. Breastfeeding women at high risk of having COVID-19 with a severe course can be vaccinated upon request.

- For patients with uncontrolled epilepsy and other neurological diseases such as Guillain-Barré Syndrome or transverse myelitis at risk for exacerbation either by COVID-19 infection or the vaccine, the decision for vaccination should be made once medical advice by a professional has been sought.
- Immunocompromised individuals should be vaccinated based on the evaluation of the clinician within an ideal period, in which the vaccine response will be stronger. It should be administered as a total of two doses, each dose four weeks apart.
- Intramuscular injection may cause bleeding in patients with thrombocytopenia and bleeding disorders.
- People with a history of allergy/anaphylaxis against any substance contained in the vaccine should not be vaccinated.
- In case of anaphylaxis development after the first dose of the COVID-19 vaccine, the second dose should not be administered.

REPUBLIC OF TURKEY
MINISTRY OF HEALTH

ADMINISTRATION RULES FOR THE INACTIVATED COVID-19 VACCINE

covid19asi.saglik.gov.tr
/SaglikBakanligi

GENERAL INFORMATION

- The inactivated COVID-19 vaccine (CoronaVac) is packaged in a single-dose, ready-to-use vial without an injector.
- 1 dose is 0.5 ml.
- It is injected intramuscularly at a dose of 0.5 ml at an angle of 90° to people aged 18 years and older.
- One dose each four weeks apart, a total of two doses are administered to people aged 18 and older.
- The administration should be performed with a standard vaccine syringe.
- It should be shaken well before use.
- It is preferable to inject the vaccine to the left arm in order to follow-up adverse effects after vaccination.
- The vaccine should be injected to the patient in a sitting position.
- After the vaccine administration, the person should be informed about possible allergic reactions and it should be ensured that the person does not leave the health facility for 15 minutes (for 30 minutes for people with a history of allergy). S/he should be told that if any side effects develop in a later period, s/he should seek medical advice.
- The vaccine is sensitive to daylight and should be duly protected from sunlight.
- It is sensitive to freezing. Care should be taken not to freeze the vaccine and it should be stored between +2 to +8°C. It can be stored on any shelf of the vaccine refrigerator cabinet. In no-frost refrigerators that do not have a vaccine refrigerator cabinet feature, they should preferably be stored on the second shelf from the top and close to the cover of the shelf so that they do not touch the inner wall of the cabinet and do not fall in front of the blowing channels. There should preferably be a freezing indicator in the refrigerator cabinet. Cold chain compliance with the Circular on The Expanded Programme on Immunization (EPI) should be provided.
- Planning should be made so that the inactivated COVID-19 vaccine (CoronaVac) will be administered immediately after opening the vial.
- Both doses of vaccination should be done with the same pandemic vaccine.
- The data matrix must be scanned before vaccination. Information on vaccination will be saved by accessing the “AŞILA” (VACCINATE!) mobile application.
- Early and late adverse effects that may occur after the administration of COVID-19 vaccines will be reported through the Public Health Management System (HSYS), Family Medicine Information System (AHBS), or Hospital Information Management System (HBYS).
- Vaccine administration steps can be followed from the "Inactivated Pandemic COVID-19 Vaccine (CoronaVac) Administration Checklist".

ADMINISTRATION WITH OTHER VACCINES AND TREATMENTS

- There is no clinical trial data on the effect of concomitant (before, after, or simultaneously) administration of other vaccines on the immunogenicity of the COVID-19 vaccine. However, taking account of other inactivated vaccine administrations and evaluating the status of the person regarding COVID-19 risk group are necessary for the following concerns:
  - It is appropriate to leave at least two weeks (before and after) between the inactivated pandemic COVID-19 vaccination, and seasonal influenza, pneumococcal, meningococcal, and other inactivated routine vaccines.
  - Between the inactivated pandemic COVID-19 vaccination and live vaccines, it is appropriate to leave at least four weeks (before and after).
- There is no time restriction for the administration of post-exposure prophylaxis vaccines such as rabies and tetanus for COVID-19 vaccine application.